| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-08-19 |
| タイトル |
|
|
タイトル |
Development of blood-brain barrier-penetrating antibodies for neutralizing tick-borne encephalitis virus in the brain |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
tick-borne encephalitis virus |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
blood-brain barrier |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
rabies virus glycoprotein |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
recombinant antibody |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Fukuta, Mizuki
Fukano, Sayo
Maekawa, Naoya
Kobayashi, Shintaro
Okamoto, Shunsuke
Hirano, Minato
Nio-Kobayashi, Junko
Kariwa, Hiroaki
Kawakami, Shigeru
Konnai, Satoru
Yoshii, Kentaro
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Tick-borne encephalitis virus (TBEV) belongs to the genus Flavivirus and causes tick-borne encephalitis (TBE), a disease characterized by severe neurological symptoms with a high mortality rate. Currently, no specific antiviral treatments have been developed for TBE. The blood-brain barrier (BBB) restricts drug delivery to the central nervous system, posing a major challenge in developing effective therapies targeting TBEV in the brain. In this study, we developed recombinant anti-TBEV antibodies fused with BBB-penetrating rabies virus glycoprotein (RVG) peptides to facilitate their transport across the BBB. The fusion of RVG peptides to the C-terminus of the heavy chain of whole antibodies or single-chain variable fragment had minimal impact on their neutralizing ability against TBEV. The RVG fusion enhanced antibody binding to the surface of a human brain endothelial cell line and increased permeability in an in vitro BBB model. The RVG-fused antibodies exhibited a higher transport efficiency to the brain than the non-fused antibodies following peripheral injection in mice. Notably, the peripheral administration of the RVG-fused whole antibody after viral invasion into the brain significantly neutralized TBEV in the brains of infected mice. These findings suggest that RVG-fused antibodies represent a promising therapeutic strategy for treating TBE once the virus has entered the brain. |
|
言語 |
en |
| 書誌情報 |
en : mSphere
巻 10,
号 7,
p. art. no. e00184-25,
発行日 2025-07-07
|
| 出版者 |
|
|
出版者 |
American Society for Microbiology |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2379-5042 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1128/msphere.00184-25 |
| 権利 |
|
|
権利情報 |
© 2025 Fukuta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
mSphere, 10(7). art. no. e00184-25; 2025 |
|
言語 |
en |
MS10_e00184-25.pdf (1.1 MB)
